(8R,9R,10R,13R,14R,17R)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8R,9R,10R,13R,14R,17R)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₂₁H₃₀O₂
• 分子量: 314.5
• InChiKey: RJKFOVLPORLFTN-ZPLOVTKXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHOD FOR INHIBITING THE PROLIFERATION OF HEPATIC STELLATE CELLS WITH A LIGAND OF THE LOW AFFINITY GLUCOCORTICOID BINDING SITE (LAGS)
  申请人：The University Court of The University of Aberdeen

  公开号：EP1435966A2

  公开（公告）日：2004-07-14
• [EN] COMPOSITIONS FOR THERAPY<br/>[FR] COMPOSITIONS THERAPEUTIQUES
  申请人：UNIV ABERDEEN

  公开号：WO2003026670A2

  公开（公告）日：2003-04-03

  Provided are methods of inhibiting proliferation and/or trans-differentiation of hepatic stellate cells, which method comprises the step of contacting hepatic stellate cells with a ligand of the low affinity glucocorticoid binding site (LAGS), which may be the rat p28 receptor or the human hpr6.6 receptor. The invention also provides ligands for use in such methods (e.g. pregnenolone 16-alpha carbonitrile) and methods for screening for the same (e.g. based on competition or displacement assays using LAGS ligands such as dexamethasone). Such ligands may be used in the treatment of liver disorders.